[Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments].
The standard therapy of ulcerative colitis and Crohn's disease is based on the treatment with corticosteroids, sulfasalazine and 5-aminosalicylic acid (mesalazine). Depending on the localization and the extent of bowel inflammation these drugs are given topically (proctosigmoiditis, left-side colitis) or systemically (total and subtotal colitis). Azathioprin and metronidazole are considered to be reserve drugs (the latter one having proven to be effective only in Crohn's disease). During the last years, the efficacy of several new agents has been investigated. At present, their routine administration cannot be advised. The clinical usefulness of new topical corticosteroids showing both high antiinflammatory effect and no or at least minor systemic side effects is promising.
Fischbach
W
W
Medizinische Poliklinik, Universität Würzburg.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D019804:Mesalamine; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D012460:Sulfasalazine; D019804:Mesalamine; D015122:Mercaptopurine; D001379:Azathioprine
Medikamentöse Therapie chronisch entzündlicher Darmerkrankungen--Bewährte Standards und neue Entwicklungen.